Eric I. Richman
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Eric I. Richman
Earlier roles on record: Board Member at Gain Therapeutics, Inc. (GANX) until October 6, 2025 and CEO at Gain Therapeutics, Inc. (GANX) until September 20, 2022. Gain Therapeutics, Inc. reported in an 8-K filed October 9, 2025 that Eric I. Richman resigned as Board of Directors, effective October 6, 2025. Gain Therapeutics, Inc. reported in an 8-K filed September 20, 2022 that Eric I. Richman resigned as Chief Executive Officer, effective September 20, 2022. The proxy statement of Gain Therapeutics, Inc. reports total compensation of $1,271,732 for Eric I. Richman in fiscal 2022, including a base salary of $343,192. Disclosed compensation is on record for 2 fiscal years.
“On October 6, 2025, Eric Richman notified Gain Therapeutics, Inc. (the "Company") that he was resigning from the Company's Board of Directors (the "Board"), effective immediately.”
“On September 20, 2022, Gain Therapeutics, Inc. (the "Company") announced that Eric Richman informed the Board of Directors (the "Board") of his intent to resign as Chief Executive Officer, effective immediately.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2022-09-20
-
Start not stated–2025-10-06
-
Start not stated–2022-09-20
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Gain Therapeutics, Inc. (GANX) | Former Chief Executive Officer | $343,192 | $1,271,732 |
| 2021 | Gain Therapeutics, Inc. (GANX) | Former Chief Executive Officer | $373,458 | $600,165 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.